Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed May 9, 2024 · 10-Q · 39 days after period end · 0001731122-24-000760
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$10.55M | -$13.11M | -$10.44M | -$8.16M |
| EPS Diluted | -$0.13 | -$0.17 | — | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 9, 2024 · 39 d after period end
